EFFECT OF SIMVASTATIN ON HISTOPATHOLOGY OF THE HEART AFTER 5/6 SUBTOTAL NEPHRECTOMY
Objective: This study aims to assess the condition of cardiac histopathology through hematoxylin-eosin staining in 5/6 subtotal nephrectomy
Methods: Fifteen male Swiss mice aged 3–5 months will be grouped into 3 treatment groups, namely the nephrectomy group (JSN, n=5), sham
operation (JSO, n=5), and simvastatin 20 mg/kg body weight (JSIM, n=5). The histopathology of the heart will be assessed blindly. Severity is assessed
based on scoring using a scale (−) no damage, (+) mild, (++) medium, and (+++) heavy. Assessment of severity refers to the irregularity of the heart
muscle, increased amount of connective tissue, myofibril hypertrophy, myofibril swelling, sarcoplasmic fragmentation, sarcoplasmic vacuolization,
bleeding in a myofibril, myofibril degeneration, cardiomyocyte damage, and the presence of acidophilic cytoplasm.
Results: The results showed no morphological changes in heart muscle tissue in the JSO group except for fragmentation and vacuolization in minimal
amounts of sarcoplasm (+), whereas in the JSN and JSIM groups, there was moderate damage to sarcoplasm (++) and minimal changes in myofibrils
(hypertrophy and bleeding) (+). The JSN group also found severe damage (+++) to the irregularity of the heart muscle, whereas in JSIM, only moderate
damage was found (++) to the irregularity of the heart muscle.
Conclusion: Simvastatin seems to be able to correct the irregularity of the heart muscle in the condition of 5/6 subtotal nephrectomy.
et al. Cardiovascular risk factor burden, treatment, and control among
adults with chronic kidney disease in the United States. Am Heart J
2. Bagshaw SM, Cruz DN, Aspromonte N, Daliento L, Ronco F,
Sheinfeld G, et al. Epidemiology of cardio-renal syndromes: Workgroup
statements from the 7th ADQI consensus conference. Nephrol Dial
3. Quarles LD. Reducing cardiovascular mortality in chronic kidney
disease: Something borrowed, something new. J Clin Invest
4. Pecoits-Filho R, Bucharles S, Barberato SH. Diastolic heart failure
in dialysis patients: Mechanisms, diagnostic approach, and treatment.
Semin Dial 2012;25:35-41.
5. U.S. Renal Data System (USRDS). Chronic Kidney Disease in the
Adult NHANES Population. USRDS Annual Report Data; 2009.
Available from: http://www.usrds.org/USRDS/pdf/V1 01 09.PDF. [Last
accessed on 2019 Mar 25].
6. Deedwania PC, Javed U. Statins in heart failure. Cardiol Clin
7. Miura S, Saku K. Effects of statin and lipoprotein metabolism in heart
failure. J Cardiol 2010;55:287-90.
8. Cahyawati PN, Arfian N, Ngatidjan N. Effect of statin on vascular
wall thickness in kidney disease model. IOP Conf Ser Mater Sci Eng
9. Cahyawati PN, Ngatidjan N, Sari DC, Romi MM, Arfian N. Simvastatin
attenuates renal failure in mice with a 5/6 subtotal nephrectomy. Int J
Pharm Pharm Sci 2017;9:12-7.
10. Cahyawati PN, Aryastuti AA, Ariawan MB, Arfian N, Ngatidjan N.
Statin and Anemia in Chronic Kidney Disease (CKD): An Experimental
Study. MATEC Web of Conferences 197; 2018.
11. Alihemmati A, Yousefi H, Ahmadiasi N, Habibi P. Apoptosis and
histopatology of the heart after renal ischemia-reperfusion in male rat
running title: Ischemia-reperfusion injury. Braz Arch Biol Thechnol
12. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG,
Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is
ameliorated by reducing circulating levels of a non-dialysable uremic
toxin, indoxyl sulfate. PLoS One 2012;7:e41281.
13. López B, González A, Hermida N, Laviades C, Díez J. Myocardial
fibrosis in chronic kidney disease: Potential benefits of torasemide.
Kidney Int Suppl 2008;111:S19-23.
14. Rodrigues Díez R, Rodrigues-Díez R, Lavoz C, Rayego-Mateos S,
Civantos E, Rodríguez-Vita J, et al. Statins inhibit angiotensin II/Smad
pathway and related vascular fibrosis, by a TGF-?-independent process.
PLoS One 2010;5:e14145.
15. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is
linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin
with concomitant increase in nitric oxide bioavailability. Am J Physiol
Renal Physiol 2008;295:F53-9.
16. Kavazis AN. Pathological vs. Physiological cardiac hypertrophy.
J Physiol 2015;593:3767.
This work is licensed under a Creative Commons Attribution 4.0 International License.